Navigation Links
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
Date:3/24/2009

fficer. "In addition, this accretive transaction provides us the opportunity to increase our net cash position, further strengthening our already strong balance sheet, and is consistent with our goal of increasing shareholder value."

From time to time, ViroPharma may evaluate additional opportunities for purchases of its common stock or convertible notes, including through open market purchases or individually negotiated transactions.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain st
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
2. ViroPharma to Present at Three November Healthcare Conferences
3. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
4. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
5. ViroPharma to Present at Three October Healthcare Conferences
6. ViroPharma to Present at Three September Healthcare Conferences
7. ViroPharma To Acquire Lev Pharmaceuticals
8. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma to Present at Two Upcoming Healthcare Conferences
11. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Selexis SA, a ... Research Cell Banks (RCBs) used for drug discovery to ... Banks will include Next-Generation Sequencing (NGS) data ... de-risks biologic manufacturing by ensuring the integrity of the ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Push of a Button , , CLEVELAND, June 4 ... the patented probiotic strain Ganeden BC30 (R), today announced a ... beverage using PowerCap(R) technology, the innovative bottle cap dispensing system. ... with the press of a button, creating a new category ...
... Scientific Sessions , , SAN FRANCISCO, June 4 ... a biotechnology company focused on the development of compounds ... today that preclinical data related to diacylglycerol acyl transferase ... poster presentation at the 69th Scientific Sessions of the ...
... a.m. EDT , , WALTHAM, Mass., June 4 ... Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... at 10:00 a.m. EDT, to report fourth quarter and fiscal year ... Company. , , This call is being webcast by Thomson/CCBN ...
Cached Biology Technology:Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 2Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... market, reports on the recent success of the Wocket™ smart wallet at ... Wocket smart wallet was named as one of the "11 Hot Products ... Best Products Launched At CES So Far" by Newseveryday.com and "The top ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... diabetes expert. He heads the Institute for Diabetes and ... the scientific director of the Helmholtz Diabetes Center (HDC). ... of Metabolic Diseases at the Technische Universitt Mnchen (TUM). ... the control of fat and sugar metabolism, with the ...
... of Warwick have modelled an outbreak of the bee infection ... applied to other honeybee diseases such as European foulbrood and ... how bee infections spread, the method also allows scientists to ... efficacy. The researchers used two sets of data gathered ...
... oxygen reservoir, which might provide a minimal, but ... anoxic conditions. A research team from China Medical ... carrying green fluorescent protein as the carrier to ... methods. Then, the recombinant plasmid was transfected into ...
Cached Biology News:Model of dangerous bee disease in Jersey provides tool in fight against honeybee infections 2